From survodutide titration to oral PCSK9 adherence and HF care models, AHA 2026 experts pointed to pharmacists as key to putting new data into practice.
|Videos|December 21, 2015
Documentation and Communication a Pharmacist Can Provide in Emergency Situations
Aaron Steffenhagen, PharmD, BCPS, clinical pharmacy manager at University of Wisconsin Hospital and Clinics, discusses what documentation and communication a pharmacist could provide in emergency situations.
Advertisement
Aaron Steffenhagen, PharmD, BCPS, clinical pharmacy manager at University of Wisconsin Hospital and Clinics, discusses what documentation and communication a pharmacist could provide in emergency situations.
This video was recorded at the 2015 American Society of Health-System Pharmacists Midyear Meeting.
Advertisement
Related to this article
Christie Ballantyne, MD, says high extension enrollment and a single 20-mg daily dose are encouraging signs for patient adherence to oral enlicitide.
An ASRA-recognized quality improvement project draws attention to injectate reproducibility, offering a starting point for examining medication preparation and pharmacists’ role in safer pain procedures.
A meta-analysis presented at IDWeek 2026 found responses were stronger after chemotherapy but waned within a year, supporting a 2-dose strategy.
How should a factor XIa inhibitor be incorporated into secondary stroke prevention?
Inconsistent state immunization laws complicate pharmacy operations and limit patient access.
Pharmacists can strengthen opioid safety through individualized counseling, overdose prevention, and coordinated follow-up that keeps patients involved in treatment decisions.
OCEANIC-STROKE supports a potential additional antithrombotic approach for select patients after noncardioembolic stroke or high-risk TIA.
Advertisement
Advertisement
Trending on Pharmacy Times
1
From Recognition to Prior Authorization: ATTR-CM Diagnosis Gaps
2
Earlier PRRT in Neuroendocrine Tumors Puts Pharmacists at the Center of Coordination
3
AHA 2026: Pharmacists at the Center of Cardiometabolic Care
4
FDA Approves Perioperative Durvalumab Plus Enfortumab Vedotin-ejfv for MIBC
5